On the 23rd of October, the Liberal Democrats Abroad and the Liberal Democrats European Group held a discussion session with Irish Senator Timmy Dooley about the Alliance of Liberals and Democrats for Europe’s contribution to the Conference on the Future of Europe. Mr Dooley underlined the importance of hearing British views on Europe’s future, to help learn the lessons from Brexit, meet citizens’ expectations, and shape the EU into an organisation that the British people would be excited to rejoin.
In health, he mentioned the disillusionment caused by an initially slow response to vaccine procurement. Things have vastly improved since then, although, this is an important opportunity to take stock of what Europe does in health – and what else we might like it to do.
Firstly, on pharmaceuticals. Manufacturers can apply to the European Medicines Agency for EU-wide marketing authorisation for their products, but that doesn’t automatically mean they’ll be available across the EU. Medicine pricing and reimbursement decisions are up to the Member States of the EU. Some have joined together to evaluate the impact of these newly available medicines and decide pricing, such as the Beneluxa group. Is there more Europe can do in this area? Should such coalitions expand to include other EU members – and could the UK get involved?
Europe also offers manufacturers incentives, based on market exclusivity for their new product for a period of time before competing medicines can come into play. The European Commission is examining changes to the rules, which could make these incentives conditional on EU-wide product availability or meeting health needs not yet addressed by existing products. At the same time, it seeks to make the process of getting market authorisation more efficient and less expensive, while maintaining high standards. Should it reform these incentives to influence manufacturers’ behaviour, and if so, how can the EU balance those two issues in a way that works for manufacturers and patients?
The Commission is also reviewing the rules on children’s and rare disease medicines, for similar reasons – how can we incentivise these treatments and make sure patients can access them?
Follow @libdemvoice.org on Bluesky
Like us on Facebook
Subscribe to our feed
Sign-up for our daily email digest
Bob Trubshaw revisits the Ironstone quarries of Leicestershire
Ex-Conservative campaign director sentenced over election bets
The Burnham government: the shine dims.
The hopes of the world rest on the shoulders of libtards in the midterm elections in the USA
Plaid Cymru bottle council tax reform
Ynys Mon Man 
Tim 
Simon Robinson 
Peter Davies 
cim 